Aug 7 (Reuters) - Biocryst Pharmaceuticals Inc
* Biocryst reports second quarter 2017 financial results
* Q2 loss per share $0.21
* Q2 revenue $3.1 million versus $4.8 million
* Q2 revenue view $5.8 million — Thomson Reuters I/B/E/S
* Q2 earnings per share view $-0.19 — Thomson Reuters I/B/E/S
* Biocryst Pharmaceuticals - continues to expect 2017 net operating cash use to be $30 million to $50 million, 2017 operating expenses to be $53 million to $73 million
* Biocryst Pharmaceuticals Inc - after discussions with FDA, NIAID and BARDA, delayed initiation of Galidesivir IV phase 1 clinical trial
* Biocryst - expect next step in Galidesivir’s development to be to conduct additional nonclinical efficacy study in delayed treatment setting in ebola disease Source text for Eikon: Further company coverage:
